NGL COVID-19 Spike Protein Affinity Resin
Novel SARS CoV-2 specific affinity resin enables a high purity capture step, decreased process time, and yield improvement for the commercial production of COVID-19 vaccines.
SARS CoV-2 specific affinity resin for the purification of COVID-19 vaccines
Novel affinity resin for the purification of the SARS CoV-2 Spike Protein for vaccine development and manufacturing
The result of close work with Navigo Proteins on the ligand development and partnership with Purolite Life Sciences on Praesto®agarose bead technology, the new NGL COVID-19 Spike Protein Affinity Resin from Repligen binds the SARS CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. The product meets all the expected requirements of a high-performance resin, including very high selectivity, high dynamic binding capacities and caustic stability over multi-cycle use.
The resin is available in off-the shelf, pre-packed and pre-qualified OPUS® Columns for rapid implementation as well as in loose resin formats.
Single-step affinity chromatography with high resolution
NGL COVID-19 Spike Protein Affinity Resin key features include:
- Single-step purification of SARS-CoV-2 spike protein RBD containing modalities*
- Compatible with 0.1N NaOH for CIP
- High binding capacity **
Optimized bead chemistry delivers exceptional purity
NGL COVID-19 Spike Protein Affinity Resin delivers >90% purity in one chromatography step.
SDS-PAGE gel of the SARS-CoV-2 Spike protein Receptor Binding Domain (RBD) expressed in HEK293 cells and purified with NGL COVID-19 Spike Protein Affinity Resin.
SPEED TO MARKET
Available pre-packed in OPUS® Columns for quick deployment
The NGL COVID-19 Spike Protein Affinity Resin is available in off-the shelf, pre-packed and pre-qualified OPUS® Columns for rapid GMP implementation as well as in loose resin formats.
OPUS® Columns allow you to progress from development to manufacturing scale in weeks, using pre-packed and pre-qualified chromatography columns.
Manufacturing Centers of Excellence
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
Repligen manufacturing sites are located in Massachusetts, California, and New Jersey in the United States and in Sweden, France, The Netherlands, Germany and Estonia.
Support is part of the Repligen DNA. Our goal is to provide exceptional customer experience, and to support the efficient and successful adoption and implementation of all Repligen products and services.
- Field Application Support
- Customer Service
- Field Service Engineers